Sartorius closes 2020 with strong growth to well over 2 billion euros and a further increase in profitability USA - English - Preliminary results for the full year of 2020: Order intake up 49.0 percent; sales revenue up 30.2 percent; underlying EBITDA margin climbs to 29.6 percent - Bioprocess Solutions Division with a sharp rise in sales revenue and earnings and a key role as a provider of essential technologies for vaccine production - Significant double-digit growth in the Lab Products & Services Division despite a challenging first half due to the pandemic - Number of employees rises by 17.7 percent to more than 10,600 - Strong outlook for 2021: Sales revenue set to increase by 19 percent to 25 percent